Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model

INTRODUCTION: On the basis of reductions in diabetic kidney disease (DKD) progression and major adverse cardiovascular events observed in the landmark CREDENCE trial, canagliflozin 100 mg received an extension to its EU marketing authorisation in July 2020 to include the treatment of DKD in people w...

Descripción completa

Detalles Bibliográficos
Autores principales: Willis, Michael, Nilsson, Andreas, Kellerborg, Klas, Ball, Philip, Roe, Rupert, Traina, Shana, Beale, Rebecca, Newell, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843731/
https://www.ncbi.nlm.nih.gov/pubmed/33263893
http://dx.doi.org/10.1007/s13300-020-00968-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843731/
https://www.ncbi.nlm.nih.gov/pubmed/33263893
http://dx.doi.org/10.1007/s13300-020-00968-x

Ejemplares similares